The deal is the latest in Moderna's push to expand beyond COVID as demand for the shots falls dramatically, and develop a vaccine for cancer, a dream that scientists have chased for decades with little success. Moderna is already developing a cancer vaccine with Merck, which was shown to cut the risk of recurrence or death by 44 per cent in patients with deadly skin cancer melanoma, in a mid-stage trial. It also has vaccines under development for flu and respiratory syncytial virus (RSV), among others.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment